SCHEMBL7674300

SCHEMBL7674300

CCCCn1cnc2c(OC)nc(Nc3ccc(OC)cc3)nc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.50
▸ CDK1 P06493 1/20 0.50
▸ CDK2 P24941 8/20 0.48
▸ CCNE1 P24864 7/20 0.48
▸ PDGFRA P16234 6/20 0.48
▸ PDE4B Q07343 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ TLR9 Q9NR96 4/20 0.45
▸ TLR7 Q9NYK1 3/20 0.45
▸ NPC1 O15118 1/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCNA1 P78396 1/20 0.43
▸ CDK4 P11802 1/20 0.43
▸ CCND1 P24385 1/20 0.43
▸ CCND2 P30279 1/20 0.43
▸ CCND3 P30281 1/20 0.43
▸ CCNE2 O96020 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673595 0.94 KDM4E (0.45) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7358873 0.90 CTSL (0.46) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7661515 0.90 CCNE1 (0.54) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7674302 0.86 PDGFRA (0.44) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7666144 0.86 CDK4 (0.45) CTSLCDK2CCNE1PDGFRACDK4
SCHEMBL7672863 0.86 PDGFRA (0.52) CDK2CCNE1PDGFRA
SCHEMBL7666120 0.84 PDGFRA (0.49) CTSLCDK2CCNE1PDGFRANPC1
SCHEMBL7674135 0.84 PDGFRA (0.43) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7672132 0.83 GALR2 (0.44) CTSLCDK1CDK2CCNE1PDGFRA
SCHEMBL7672897 0.82 LMNA (0.50) CDK2CCNE1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6414147-B1 DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY NEUROGEN CORPORATION 2002-07-02 — — US claimed
US-6414147-B1 DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY NEUROGEN CORPORATION 2002-07-02 — — US disclosed
Send feedback